Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
In this article:
Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.
Advertisement